Trial Profile
A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients with Paroxysmal Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ISIS CRPRx (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
- 25 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2014 Results published in an Isis Pharmaceuticals media release.
- 31 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.